Spruce Biosciences, Inc. has terminated its Collaboration Agreement with Kaken Pharmaceutical Co., Ltd. effective March 31, 2026, which previously involved a $15 million upfront payment and potential milestone payments totaling around $65 million for the development of a treatment for CAH.